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LETTER TO THE EDITOR
Soluble IL-2a and ovarian cancer
Sir - The report by Owens et al. (1993) on the interleukin-2
receptor in ovarian cancer raises a number of questions.
The interleukin-2 receptor that the authors refer to is more
correctly described as the soluble interleukin-2 receptor a.
Furthermore, in their introduction, the authors seem to be
unaware of IL-2Ry (Kamio et al., 1992; Takeshita et al.,
1992). It is not correct to state that both the 55 kDa and
75 kDa components bind IL-2 with low affinity. The current
hypothesis is that IL-2Rx binds IL-2 with low affinity, but
this receptor is not expressed on normal human cells as the
only IL-2 receptor. The intermediate-affinity receptor,
formerly designated the 75 kDa receptor, is now known to be
a heterodimeric structure of IL-2RP and IL-2Ry (Taniguchi
& Minami, 1993).
The authors state that 'To date IL-2R has been evaluated
extensively in haematological malignancies, but seldom in
ovarian cancer.' We first published results on the serum and
ascitic levels of sIL-2Ra, and correlated these with CA-125
levels (Barton et al., 1993a). The values for serum sIL-2Ra
obtained by Owens et al. (1993) are similar to those we had
reported. Our study showed that the ascitic levels of sIL-2Ra
exceeded the serum levels, an observation in keeping with the
known tendency of ovarian cancer to remain confined to the
peritoneal cavity.
Finally, we have also studied the effect of surgery on serum
sIL-2Ra levels in gynaecological cancers (Barton et al.,
1993b).
Yours etc,
D.P.J. Barton
Division of Gynecologic Oncology,
Department of Obstetrics and Gynecology,
Temple University School of Medicine,
Broad and Ontario Streets,
Philadelphia, PA 19140, USA.
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